Effects Mediated by Dimethyl Fumarate on In Vitro Oligodendrocytes: Implications in Multiple Sclerosis

• Published in: International journal of molecular sciences Vol. 23; no. 7; p. 3615
• Main Authors: Guerriero, Claudia, Puliatti, Giulia, Di Marino, Tamara, Tata, Ada Maria
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25.03.2022; MDPI
• Subjects: Anti-inflammatory agents; Antigens; Antioxidants; Cell differentiation; Cell growth; Cell proliferation; Content analysis; Cytokines; Cytology; Differentiation; dimethyl fumarate; Dimethyl Fumarate - pharmacology; Dimethyl Fumarate - therapeutic use; Disease; Gene expression; Humans; Immunocytochemistry; Immunomodulation; Immunosuppressive Agents - therapeutic use; Inflammation; Lipids; Lipids - therapeutic use; Lipopolysaccharides; Morphology; Multiple sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Neuroprotection; Oli neu cell line; Oligodendrocytes; Oligodendroglia; Oxidative stress; Polymerase chain reaction; Psoriasis; Staining; lipids; dimethyl fumarate; oligodendrocytes; multiple sclerosis; oxidative stress; Oli neu cell line

Dimethyl fumarate (DMF) is a drug currently in use in oral therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) due to its immunomodulatory and neuroprotective effects. The mechanisms by which DMF exerts its therapeutic effects in MS and in particular its influence on the oligo...